Board of Directors
Scientific Advisory Board
Antibody Drug Conjugates
Johns Hopkins University
Annual and Quarterly Reports
From the Genome to
The next wave in immuno-oncology
Therapeutic product discovery
In the information age
Jun 15, 2015
Compugen to Present at JMP Securities Life Sciences Conference in New York
Jun 08, 2015
Compugen to Disclose Novel Cancer Immunotherapy Target Candidate and Comprehensive Target Characterization Infrastructure at Today’s Analyst and Investor Day
Our optimized process for predictive discovery of novel drug targets
Discovery & development of first-in-class monoclonal antibody therapeutics
CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells ...
CGEN-15022 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15022 is expressed in numerous types of epithelial cancers, such ...
CGEN-15049 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15049 was shown to inhibit the activity of immune cells that play ...
CGEN-15027 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. Studies by Compugen have shown that this immune checkpoint target is ...
CGEN-15052 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. Initial testing of CGEN-15052 expression in human cancer tissue samples ...
CGEN-15092 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15092 Fc fusion protein was shown to inhibit activation of T cells and ...
CGEN-15001 is our lead program for autoimmune diseases. CGEN-15001 is an Fc fusion protein that contains the extracellular domain of CGEN-15001T, a novel immune ...
Jul 16, 2015
Martin Gerstel to present at The MoneyShow San Francisco
Jun 08, 2015
Compugen's Investor and Analyst Day in NYC
New York, NY
Jun 28, 2015
Compugen to participate at the Israel-German Innovation Day
Tel Aviv, Israel
In August 2013, Compugen entered into a collaboration and license agreement with Bayer HealthCare ...
In June 2012, Compugen and Merck Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, jointly ...
Click here for more info about partnering with Compugen